CPWM
CCCC icon

Cypress Point Wealth Management’s C4 Therapeutics CCCC Stock Holding History

Cypress Point Wealth Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-118,573
Closed -$2.88M – 27
2022
Q1 		$2.88M Buy
+118,573
New +$2.88M 2.92% 13

Other funds holding CCCC

ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Cypress Point Wealth Management's CCCC Position: Q2 2022 in Review

Cypress Point Wealth Management sold out of C4 Therapeutics (CCCC) in Q2 2022, closing a stake of 118,573 shares — an estimated $2.88M sold.

Cypress Point Wealth Management first reported a position in CCCC in Q1 2022 and held it in 1 quarter. The position peaked at $2.88M in Q1 2022. 113 funds tracked by Wall St. Rank hold CCCC as of Q2 2022.

  • Cypress Point Wealth Management reported no remaining C4 Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Cypress Point Wealth Management sold 118,573 C4 Therapeutics shares in Q2 2022, an estimated $2.88M.
  • Cypress Point Wealth Management first reported a position in C4 Therapeutics in Q1 2022 and held it in 1 quarter.
  • Cypress Point Wealth Management's C4 Therapeutics position peaked at $2.88M in Q1 2022.
  • 113 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2022.

Based on Cypress Point Wealth Management's 13F filing for Q2 2022, filed 8 Aug 2022.